Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial,BJU International

当前位置： X-MOL 学术 › BJU Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial
BJU International ( IF 3.7 ) Pub Date : 2021-10-27 , DOI: 10.1111/bju.15625
Yasmin Abu-Ghanem ₁ , Johannes V van Thienen ₂ , Christian Blank ₂ , Maureen J B Aarts ₃ , Michael Jewett ₄ , Igle Jan de Jong ₅ , Jean-Baptiste Lattouf ₆ , Harm H E van Melick ₇ , Lori Wood ₈ , Peter Mulders ₉ , Sylvie Rottey ₁₀ , John Wagstaff ₁₁ , Patricia Zondervan ₁₂ , Tom Powles ₁₃ , Anouk Neven ₁₄ , Laurence Collette ₁₄ , Bertrand Tombal _{14,

15} , John Haanen ₂ , Axel Bex _{1,

2}

Affiliation

Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK.
Netherlands Cancer Institute, Amsterdam, the Netherlands.
Maastricht University Medical Center, Maastricht, the Netherlands.
Princess Margaret Hospital, Toronto, ON, Canada.
University of Groningen, University Medical Center Groningen, the Netherlands.
University of Montreal Hospital Center, Montreal, QC, Canada.
Saint Antonius Hospital, Nieuwegein, the Netherlands.
QEII Health Sciences Center, Halifax, NS, Canada.
Radboud University Hospital, Nijmegen, the Netherlands.
Ghent University Hospital, Ghent, UK.
South West Wales Cancer Centre and Swansea University College of Medicine, Swansea, UK.
University Medical Centers, Amsterdam, the Netherlands.
Barts and Queen Mary University London, London, UK.
European Organisation of Research and Treatment of Cancer (EORTC), Brussels, Belgium.
Cliniques Universitaires Saint-Luc, Brussels, Belgium.

To analyse if exposure to sunitinib in the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial, which investigated opposite sequences of cytoreductive nephrectomy (CN) and systemic therapy, is associated with the overall survival (OS) benefit observed in the deferred CN arm.

中文翻译：

细胞减灭性肾切除术和舒尼替尼暴露——对苹果酸舒尼替尼治疗转移性肾癌患者的即刻手术或手术后的事后分析 (SURTIME) 试验

分析在立即手术或苹果酸舒尼替尼术后手术治疗转移性肾癌患者 (SURTIME) 试验中暴露于舒尼替尼是否与总生存期 (OS) 相关，该试验调查了细胞减灭性肾切除术 (CN) 和全身治疗的相反顺序在延迟 CN 组中观察到的益处。

更新日期：2021-10-27

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11